Last reviewed · How we verify

NCT05581524: VASC

Vacuum Assisted Sclerotherapy Performed by Catheter

Completed NA Last updated 2 May 2025
What this trial tests

NA trial testing VASC in Varicose Veins of Lower Limb in 22 participants. Completed in 31 December 2024.

Timeline
7 June 2022
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorI-VASC S.r.l
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment22
Start date7 June 2022
Primary completion31 December 2024
Estimated completion31 December 2024
Sites2 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

I-VASC S.r.l

Who can join

18 and older, any sex, with Varicose Veins of Lower Limb. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

VelexTM Venous Catheter is a venous catheter for temporary use to treat a vein isolated segment, designed for the treatment of varicose veins of lower limbs by means of chemical ablation or empty-vein sclerotherapy. V.A.S.C. is a multicentric, prospective, open label, non-randomized PMCF study of VelexTM venous catheter used according to the indication of use within the scope of the CE mark. VelexTM venous catheter is intended for patients with varicose veins of lower limbs. The total minimum number of patients is 24 and the maximum 36 for the two centers participating. Each center shall enroll at least 8 patients andno more than 28.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Varicose Veins of Lower Limb

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05581524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing